• If you are wondering whether Corteva's recent share price puts it on the expensive or attractive side, this article will walk through what the current numbers actually say about value.
• Corteva shares last closed at US$80.85, with returns of 1.3% over 7 days, a 3.5% decline over 30 days, 19.3% year to date, 30.4% over 1 year, 43.5% over 3 years and 74.8% over 5 years.
• These moves have arrived alongside ongoing interest in agricultural inputs and crop protection companies, as investors weigh how resilient earnings and cash flows could be across cycles. Broader sector attention can influence how much investors are prepared to pay for Corteva's future prospects at any given time.
• Corteva currently has a valuation score of 1 out of 6, which means it screens as undervalued on only one of six checks. The next sections will compare different valuation approaches and then finish with a broader way to think about what that score really means for you.

Corteva scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corteva Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth today by projecting future cash flows and then discounting those back into present value using a required rate of return.

For Corteva, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about US$2.8b. Analysts provide free cash flow estimates out to 2029, with US$2.7b projected for the year ending 2029. Beyond that point, Simply Wall St extrapolates further free cash flow projections up to 2035 using modest growth assumptions.

When all those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of US$93.49 per share. Compared to the recent share price of US$80.85, this implies the shares trade at about a 13.5% discount to that DCF estimate, so the stock screens as undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corteva is undervalued by 13.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Corteva Price vs Earnings

For profitable companies like Corteva, the P/E ratio is a useful way to gauge how much you are paying for each dollar of current earnings. A higher or lower P/E often reflects what the market expects for future earnings growth and how risky those earnings are perceived to be, so there is no single “right” number for all companies.

Corteva currently trades on a P/E of 45.50x. That is above the Chemicals industry average of 30.00x and also above the peer group average of 18.75x. Simply Wall St also calculates a proprietary “Fair Ratio” of 26.62x for Corteva, which is the P/E level suggested by factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio framework can be more informative than a simple comparison with peers or the industry, because it adjusts for company specific attributes instead of assuming one benchmark fits all. Comparing Corteva’s current P/E of 45.50x with the Fair Ratio of 26.62x indicates the shares trade above that tailored range.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Corteva Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple way for you to attach your own story about Corteva to the numbers by setting assumptions for its future revenue, earnings and margins, and then seeing what fair value those assumptions support.

A Narrative connects three things in a straight line: what you think is happening with Corteva’s business, how that view flows into a financial forecast, and what fair value estimate that forecast points to, so you can compare it with the current share price.

On Simply Wall St’s Community page, millions of investors use Narratives as an accessible tool that updates when fresh information such as news, guidance or earnings is added, so your fair value view does not stay stuck on old data.

For Corteva, one investor might focus on strong demand for resilient seeds, biologicals growth, cost optimization and higher future margins, and land near the higher analyst fair value range around US$96. Another might worry more about crop protection competition, currency risks and regulatory pressure and lean toward the lower end around US$74. Comparing each Narrative’s fair value to the current price helps decide whether to act or wait.

Do you think there's more to the story for Corteva? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.